Literature DB >> 34258722

Does Total Neoadjuvant Treatment Improve Overall Survival in Rectal Cancer? No, It Does Not.

Joanna Socha1,2, Krzysztof Bujko3.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34258722     DOI： 10.1245/s10434-021-10432-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  3 in total

1.  ASO Visual Abstract: A National Survey of Breast Surgeons and Radiation Oncologists on Contemporary Axillary Management in Mastectomy Patients.

Authors:  Chandler S Cortina; Carmen Bergom; Morgan Ashley Craft; British Fields; Ruta Brazauskas; Adam Currey; Amanda L Kong
Journal:  Ann Surg Oncol       Date:  2021-08-09       Impact factor: 5.344

2.  Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.

Authors:  Zhaoli Tan; Chunyan Yue; Shoujian Ji; Chuanhua Zhao; Ru Jia; Yun Zhang; Rongrui Liu; Da Li; Qian Yu; Ping Li; Zhiyuan Hu; Yanlian Yang; Jianming Xu
Journal:  Oncologist       Date:  2021-09-28

3.  Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Thierry Conroy; Jean-François Bosset; Pierre-Luc Etienne; Emmanuel Rio; Éric François; Nathalie Mesgouez-Nebout; Véronique Vendrely; Xavier Artignan; Olivier Bouché; Dany Gargot; Valérie Boige; Nathalie Bonichon-Lamichhane; Christophe Louvet; Clotilde Morand; Christelle de la Fouchardière; Najib Lamfichekh; Béata Juzyna; Claire Jouffroy-Zeller; Eric Rullier; Frédéric Marchal; Sophie Gourgou; Florence Castan; Christophe Borg
Journal:  Lancet Oncol       Date:  2021-04-13       Impact factor: 41.316
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.